AI
GILD icon

Axecap Investments’s Gilead Sciences GILD Stock Holding History

Axecap Investments’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,935
Closed -$3.43M – 77
2025
Q4 		$3.43M Sell
27,935
-16,401
-37% -$1.99M 2.11% 16
2025
Q3 		$4.92M Sell
44,336
-253
-0.6% -$28.8K 3.04% 7
2025
Q2 		$4.94M Buy
+44,589
New +$4.75M 3.22% 9

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Axecap Investments's GILD Position: Q1 2026 in Review

Axecap Investments sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 27,935 shares — an estimated $3.43M sold.

Axecap Investments first reported a position in GILD in Q2 2025 and held it in 3 quarters. The position peaked at $4.94M in Q2 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Axecap Investments reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
  • Axecap Investments sold 27,935 Gilead Sciences shares in Q1 2026, an estimated $3.43M.
  • Axecap Investments first reported a position in Gilead Sciences in Q2 2025 and held it in 3 quarters.
  • Axecap Investments's Gilead Sciences position peaked at $4.94M in Q2 2025.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Axecap Investments's 13F filing for Q1 2026, filed 20 Apr 2026.